We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Plerith works with high growth start-ups and scaling companies to plan for and deliver growth. The company asserts that it helps companies promote their business to potential funders, through its network of angel and venture capital investors depending on the stage and sector of the said business. Plerith is partnering with Newable and Bristol Private Equity Club to deliver the fund in the South West London (SWL) area and identify and invest in the most exciting high growth companies in the region. Plerith argues that its deep knowledge of fundraising, sales, strategy, finance and technology would help SWL businesses flourish. Plerith aims to provide investors access to the highest quality local companies in the SWL region.
days to go: Stretch investment: Withheld
Peerport Limited (trading as MultiISA) is targeting the multi-million-pound market and claims to offer a holistic approach to Individual Savings Account (ISA) management. The company asserts that traditional ISA managers don’t give users enough flexibility with their investment choices. Current ISA rules restrict investors to only one ISA of each type per tax year. This impedes the investors’ ability to build a diversified IFISA portfolio. Peerport argues that its portal offers investors the freedom to operate multiple accounts like Innovative Finance ISA (IFISA), Cash ISA, and Stocks & Shares ISA under a single ISA management platform. The company will use the investment to finalise the build-out of its end to end platform, fund its office space, manage marketing costs, oversee staffing costs, pay regulatory fees and supervise working capital.

Pitch Rated

88%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £6,033
With new MiFID II regulations introduced in January, Hiddensee provides independent investment research mainly on forensic accounting and corporate governance. Analysts will search for inconsistencies and anomalies in the valuation of UK listed mid-cap and smaller companies and publish their reports to assist investors in deciding whether to buy or sell shares.
days to go: Expired investment: £143,097
Muse is a smart, data-driven financial management application which aims to make financial empowerment a reality for all business owners. The app generates clear snapshots of a company’s finances showing all bank balances, and gives quick access to innovative invoice financing and other smart tools. Muse is live on the App Store and Google Play. Moreover, it has partnered with Prime 5 Finance Limited for invoice finance facility. The funds raised will be used to expand the business, sales channels and give an e-money account card in three currencies.

Pitch Rated

36%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £339,920
Meame create stylish performance fashion for the growing demand of technical clothing for a busy lifestyle. The sportswear brand enables cyclists to become more visable and stylish in comfortable performance fashion with exclusive reflective and water proof fabric. The clothing features hidden reflective strips so cyclists can be visible and protected whilst wearing fashionable pieces. 
days to go: Expired investment: £67,520
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
Forth allows users to track their wellbeing to see what impact their lifestyle is having on their health. It allows users to maximise their performance during athletics, keep track of their inner health and focus on things they may need to work on for greater overall wellbeing. 
days to go: Expired investment: £165,760
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph